-
PDS Biotech NASDAQ:PDSB PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively delivers disease-specific antigens for in vivo uptake and processing, while also activating the critical type 1 interferon immunological pathway, resulting in production of potent disease-specific killer T-cells as well as neutralizing antibodies. PDS Biotech has engineered multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize disease cells and effectively attack and destroy them.
Location: 25B Vreeland Road, Suite 300, New Jersey, 07932, United States | Website: www.pdsbiotech.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
40.65M
Cash
57.73M
Avg Qtr Burn
-8.607M
Short % of Float
12.62%
Insider Ownership
3.99%
Institutional Own.
12.36%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Versamune® HPV (PDS0101) + Keytruda Details Head and neck squamous cell carcinoma, Cancer | Phase 3 Initiation | |
PDS01ADC + Radiation Therapy Details Prostate cancer | Phase 2 Data readout | |
Versamune® HPV + PDS01ADC + pembrolizumab Details Head and neck squamous cell carcinoma, Cancer | Phase 2 Data readout | |
Versamune® HPV (PDS0101) + Keytruda Details Cancer, Solid tumor/s, HPV+ oropharyngeal cancer | Phase 2 Data readout | |
PDS01ADC + ICI Details Human papillomavirus | Phase 2 Data readout | |
Versamune® HPV (PDS0101) + Chemoradiation Details Cervical cancer, Cancer | Phase 2 Update | |
PDS0301 + Docetaxel Details Cancer, Prostate cancer | Phase 1/2 Data readout | |
PDS01ADC Details Kaposi Sarcoma | Phase 1/2 Data readout | |
PDS01ADC + Histone Deacetylase (HDAC) inhibitor Details Bladder cancer, Cancer | Phase 1/2 Data readout | |
PDS01ADC + Docetaxel Details Prostate cancer | Phase 1/2 Data readout |